Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations.
Notre service GeoIP a trouvé l'hôte europa-trial.org .Actuellement, hébergé dans France et son fournisseur de services est SFR .
Latitude:
48.853408813477
Longitude:
2.348799943924
Pays:
France (fr)
Ville:
Paris
Région:
Ile-de-France
ISP:
SFR
the related websites
Analyse d'en-tête HTTP
Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Apache contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.
Content-Length: 11630 Via: 1.1 varnish (Varnish/6.0), 1.1 varnish (Varnish/6.0) X-Cache: HIT X-Powered-By: PHP/7.0.27 Accept-Ranges: bytes Content-Encoding: gzip Vary: Accept-Encoding Server: Apache Connection: keep-alive Link: Date: Mon, 13 Aug 2018 15:45:43 GMT X-Cache-Hits: 1 Content-Type: text/html; charset=UTF-8 Age: 81
DNS
soa: ns1.markmonitor.com. hostmaster.markmonitor.com. 2017051001 86400 3600 2592000 172800 ns: ns6.markmonitor.com. ipv4: IP:37.70.226.53 15557 LDCOMNET, FR FR 62.23.38.165 8220 COLT, GB GB
HtmlToText
our company governance global presence key figures story vocation and values culture financial results servier institute our products servier medicines generic drugs e-health solutions fight against counterfeiting areas of expertise research & development research axis development portfolio clinical trials paediatric expertise regulatory affairs pharmacovigilance medical promotion industry industrial quality production supply chain cdmo services medical affairs business development & licensing cross-functional activities our commitments patients’ in ethics compliance policy csr approach servier endowment fund newsroom news press release decoded content career partnering press fr servier : an international pharmaceutical group governed by a non-profit foundation read more we are focused on cardiovascular diseases, cancer , diabetes , immune-inflammatory and neuropsychiatric diseases read more we contribute to transmit to future generations a world that can ensure access to quality health care for all read more we are committed to therapeutic progress to serve patient needs read more with 94 million patients treated worldwide by our medicinal products on a daily basis, we are keenly aware of our responsibilities towards patients, doctors, and healthcare professionals. they are the motivating force behind our daily drive for innovation as a provider of therapeutic progress . latest news servier group appoints david k. lee as ceo of servier pharmaceuticals (us) 16 / 07 / 2018 press release ishr-es – servier research fellowship 2018 awarded to dr. francesca bortolotti 06 / 07 / 2018 news servier netherlands mobilizes for stem cell donation 04 / 07 / 2018 news how to manufacture a biomedicine? 29 / 06 / 2018 decoded content servier and galapagos announce start of global roccella phase 2 clinical trial with s201086/glpg1972 in osteoarthritis 27 / 06 / 2018 press release servier algeria: joy for hospitalized children 19 / 06 / 2018 news wehealth by servier joins forces with peter sheehan diabetes care foundation in the fight against diabetes 12 / 06 / 2018 press release world anti-counterfeiting day: servier – on the front line against the falsification of medicines 06 / 06 / 2018 news because i say so, a servier campaign against hypertension 01 / 05 / 2018 news servier backs the research project of an american startup in the field of oncology 26 / 04 / 2018 press release discover our business review rapport d'activité 2016 - 2017 our company governance global presence key figures story vocation and values culture financial results servier institute our products servier medicines generic drugs e-health solutions fight against counterfeiting areas of expertise research & development research axis development portfolio clinical trials paediatric expertise regulatory affairs pharmacovigilance medical promotion industry industrial quality production supply chain cdmo services medical affairs business development & licensing cross-functional activities our commitments patients’ in ethics compliance policy csr approach servier endowment fund newsroom news press release decoded content career partnering press legal mentions data privacy contact us report a side effect fr © servier – latest update : august 2018. we use cookies to ensure that we give you the best experience on our website. if you continue to use this site we will assume that you are happy with it. ok no read more
Top search words for europa-trial.org diseases , cardiovascular , diseases. , diabetes , focused , neuropsychiatric , cancers , immune-inflammatory , research ,
Analyse PopURL pour europa-trial.org
https://servier.com/en/legal-mentions/
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
WHOIS LIMIT EXCEEDED - SEE WWW.PIR.ORG/WHOIS FOR DETAILSREFERRER http://www.pir.org/REGISTRAR Public Interest RegistrySERVERS SERVER org.whois-servers.netARGS europa-trial.orgPORT 43TYPE domainRegrInfo REGISTERED unknownDOMAIN NAME europa-trial.orgNSERVER NS2.MARKMONITOR.COM 162.88.60.13NS1.MARKMONITOR.COM 64.124.69.50NS4.MARKMONITOR.COM 162.88.60.15NS3.MARKMONITOR.COM 162.88.61.15NS6.MARKMONITOR.COM 162.88.60.17NS7.MARKMONITOR.COM 162.88.61.19NS5.MARKMONITOR.COM 162.88.61.17
Go to top
europa-trial.org rapport :
Visitez le site